Trial Search Results
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
Alliance for Clinical Trials in Oncology
Collaborator: National Cancer Institute (NCI)
- Drug: cyclophosphamide
- Drug: cytarabine
- Drug: daunorubicin hydrochloride
- Drug: dexamethasone
- Drug: doxorubicin hydrochloride
- Drug: mercaptopurine
- Drug: methotrexate
- Drug: pegaspargase
- Drug: thioguanine
- Drug: vincristine sulfate
- Radiation: radiation therapy
1. Newly diagnosed patients with either B-precursor or T-precursor acute
lymphoblastic leukemia (WHO criteria). Burkitt type leukemia as defined per
protocol is not eligible. Patients known to have Ph+ ALL at time of diagnosis are
2. CALGB patients entered on CALGB 10403 who are later found to meet the following
criteria for Ph+ ALL should have treatment on this trial discontinued and should
be encouraged to enroll on CALGB 10001 or its successor trial:
- BCR-ABL fusion transcript determined by FISH or RT-PCR
- t(9;22)(q34;q11) or variant determined by cytogenetics
Non-CALGB study participants who are later found to be Ph+ should have treatment on
this trial discontinued and should be encouraged to enroll on an appropriate clinical
trial specifically designed for Ph+ ALL.
2. Age: 16 - 39 years
3. ECOG Performance Status 0-2
4. Patients with Down Syndrome are excluded from this study due to the likelihood of
excessive toxicity resulting. These patients should be treated in consultation with a
5. Prior Therapy - No prior therapy except for limited treatment with corticosteroids or
hydroxyurea and a single dose of intrathecal cytarabine.
1. No prior therapy for acute leukemia except emergency therapy (corticosteroids or
hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure
due to leukemic infiltration of the kidneys. When indicated, leukapheresis or
exchange transfusion is recommended to reduce the WBC.
2. Single-dose intrathecal cytarabine is allowed prior to registration or prior to
initiation of systemic therapy for patient convenience. This is usually done at
the time of the diagnostic bone marrow or venous line placement to avoid a second
lumbar puncture. Systemic chemotherapy must begin within 72 hours of this
3. Patients receiving prior steroid therapy are eligible for study. The dose and
duration of previous steroid therapy should be carefully documented on case
Ages Eligible for Study
16 Years - 39 Years
Genders Eligible for Study